Candriam adds to team dedicated to biotech


p { margin-bottom: 0.25cm; line-height: 120%; } Candriam Investors Group has announced that it is adding to its team dedicated to the healthcare sector, with the appointment of Tasuku Kitada as senior biotechnology analyst. As part of the biotechnology sector equity strategy at Candriam, Kitada will focus in particular on cutting-edge technologies such as gene therapy and RNA interference. Kitada, a graduate of the University of Tokyo in biophysics and biochemistry, with a doctorate in molecular biology from the university of California, has served as a postdoctorate researcher in biochemistry. More recently, he served as a post-doctoral partner in synthetic biology at the Massachusetts Institute of Technology (MIT).